Ceregene, Inc.
http://www.ceregene.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ceregene, Inc.
IPOs Collapse In The Second Quarter
Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation
Ekso Bionics’ exoskeleton received a final payment determination from the Centers for Medicare and Medicaid Services, paving the way to faster rehabilitation for more patients.
Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal
Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice